Tricaprilin is under clinical development by Cerecin and currently in Phase II for Infantile Spasm (West Syndrome). According to GlobalData, Phase II drugs for Infantile Spasm (West Syndrome) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tricaprilin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tricaprilin overview
Tricaprilin (AC-1204) is under development for the treatment of Alzheimer’s disease, migraine, infantile spasms (West syndrome). The drug candidate is administered orally. The therapeutic candidate is a formulation of caprylic triglyceride. Caprylic triglyceride is a long-chain triglyceride which acts by boosting cellular metabolism. The drug candidate was also under development for dementia, Parkinson's disease, epilepsy and cognitive impairment in Multiple sclerosis.
Cerecin overview
Cerecin, formerly Accera, is a biopharmaceutical company that discovers and develops drugs for the treatment of neurological diseases. It is investigating Tricaprilin, a proprietary oral formulation of a medium chain triglyceride against Alzheimer’s and Parkinson’s disease, migraine and epilepsy. The company’s drug candidate produces ketosis which helps in improving mitochondrial metabolism. Cerecin works in partnership with University of Minnesota, EDB Singapore, Wilmar International Ltd and other companies. It has operational presence in Colorado, the US; and Victoria, Australia. Cerecin is headquartered in Singapore City, Singapore.
For a complete picture of Tricaprilin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
